Strata Skin Sciences Q3 2025 Earnings Report

Strata Skin Sciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.24
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Strata Skin Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $7.72 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Strata Skin Sciences Announcement Details

• Quarter: Q3 2025
• Date: 11/12/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 12, 2025
• Conference Call Time: 4:30PM ET

Strata Skin Sciences (NASDAQ:SSKN) is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof. This integration enabled the company to widen its geographic footprint, serving physicians and clinics across the United States and through select international distribution partners in Europe and Asia. Strata continues to invest in clinical research, product enhancements and next-generation platforms aimed at addressing a range of dermatologic disorders with noninvasive treatment modalities.

Under the leadership of Chairman and Chief Executive Officer David J. Peskin, Strata Skin Sciences maintains a direct sales force of clinical specialists who provide installation, training and ongoing support for its laser and light‐based systems. The company’s operational strategy focuses on fostering long-term partnerships with dermatology practices, promoting the adoption of its technologies through peer-reviewed publications, educational initiatives and real-world evidence studies. As a result, Strata has positioned itself as a focused provider of advanced phototherapy solutions within the skin disease market.